Meccanismi neuroumorali nello scompenso cardiocircolatorio.

Translated title of the contribution: Neurohumoral mechanisms in cardiocirculatory decompensation

G. Grassi, G. Mancia

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Congestive heart failure is characterized by profound alterations in systemic haemodynamics as well as in neurohumoral profile with activation of the sympathetic nervous system, reninangiotensin axis, plasma vasopressin and atrial natriuretic peptides, i.e. factors involved in homeostatic control of the cardiovascular system. The sympathetic stimulation, which has been documented by a variety of methodological approaches (plasma norepinephrine measurement, norepinephrine spillover technique, microneurographic recording of efferent post-ganglionic muscle sympathetic nerve traffic) is already evident in the initial stages of the disease (NYHA classes I-II) and more manifest in severe heart failure (NYHA classes III-IV). Although representing in mild heart failure a compensatory mechanism aimed at preserving cardiac output, the sympathetic and neurohumoral activation, which can be likely ascribed to arterial baroreceptor dysfunction, may represent, in the clinical course of the disease, a maladaptative phenomenon. Thus pharmacological treatment of heart failure should be aimed not only at improving systemic haemodynamics but also at reversing neurohumoral activation and baroreflex impairment. Recent experimental clinical evidence suggests that these therapeutical goals can be satisfactorily achieved by digitalis glycosides and ACE-inhibitors.

Original languageItalian
JournalAnnali Italiani di Medicina Interna
Volume9 Suppl
Publication statusPublished - Oct 1994

Fingerprint

Heart Failure
Norepinephrine
Hemodynamics
Digitalis Glycosides
Pressoreceptors
Baroreflex
Sympathetic Nervous System
Atrial Natriuretic Factor
Cardiovascular System
Treatment Failure
Vasopressins
Angiotensin-Converting Enzyme Inhibitors
Cardiac Output
Pharmacology
Muscles

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Meccanismi neuroumorali nello scompenso cardiocircolatorio. / Grassi, G.; Mancia, G.

In: Annali Italiani di Medicina Interna, Vol. 9 Suppl, 10.1994.

Research output: Contribution to journalArticle

@article{82984e067d3b4ae1a5adfc1bdc09477b,
title = "Meccanismi neuroumorali nello scompenso cardiocircolatorio.",
abstract = "Congestive heart failure is characterized by profound alterations in systemic haemodynamics as well as in neurohumoral profile with activation of the sympathetic nervous system, reninangiotensin axis, plasma vasopressin and atrial natriuretic peptides, i.e. factors involved in homeostatic control of the cardiovascular system. The sympathetic stimulation, which has been documented by a variety of methodological approaches (plasma norepinephrine measurement, norepinephrine spillover technique, microneurographic recording of efferent post-ganglionic muscle sympathetic nerve traffic) is already evident in the initial stages of the disease (NYHA classes I-II) and more manifest in severe heart failure (NYHA classes III-IV). Although representing in mild heart failure a compensatory mechanism aimed at preserving cardiac output, the sympathetic and neurohumoral activation, which can be likely ascribed to arterial baroreceptor dysfunction, may represent, in the clinical course of the disease, a maladaptative phenomenon. Thus pharmacological treatment of heart failure should be aimed not only at improving systemic haemodynamics but also at reversing neurohumoral activation and baroreflex impairment. Recent experimental clinical evidence suggests that these therapeutical goals can be satisfactorily achieved by digitalis glycosides and ACE-inhibitors.",
author = "G. Grassi and G. Mancia",
year = "1994",
month = "10",
language = "Italian",
volume = "9 Suppl",
journal = "Annali Italiani di Medicina Interna",
issn = "0393-9340",
publisher = "CEPI s.r.l.",

}

TY - JOUR

T1 - Meccanismi neuroumorali nello scompenso cardiocircolatorio.

AU - Grassi, G.

AU - Mancia, G.

PY - 1994/10

Y1 - 1994/10

N2 - Congestive heart failure is characterized by profound alterations in systemic haemodynamics as well as in neurohumoral profile with activation of the sympathetic nervous system, reninangiotensin axis, plasma vasopressin and atrial natriuretic peptides, i.e. factors involved in homeostatic control of the cardiovascular system. The sympathetic stimulation, which has been documented by a variety of methodological approaches (plasma norepinephrine measurement, norepinephrine spillover technique, microneurographic recording of efferent post-ganglionic muscle sympathetic nerve traffic) is already evident in the initial stages of the disease (NYHA classes I-II) and more manifest in severe heart failure (NYHA classes III-IV). Although representing in mild heart failure a compensatory mechanism aimed at preserving cardiac output, the sympathetic and neurohumoral activation, which can be likely ascribed to arterial baroreceptor dysfunction, may represent, in the clinical course of the disease, a maladaptative phenomenon. Thus pharmacological treatment of heart failure should be aimed not only at improving systemic haemodynamics but also at reversing neurohumoral activation and baroreflex impairment. Recent experimental clinical evidence suggests that these therapeutical goals can be satisfactorily achieved by digitalis glycosides and ACE-inhibitors.

AB - Congestive heart failure is characterized by profound alterations in systemic haemodynamics as well as in neurohumoral profile with activation of the sympathetic nervous system, reninangiotensin axis, plasma vasopressin and atrial natriuretic peptides, i.e. factors involved in homeostatic control of the cardiovascular system. The sympathetic stimulation, which has been documented by a variety of methodological approaches (plasma norepinephrine measurement, norepinephrine spillover technique, microneurographic recording of efferent post-ganglionic muscle sympathetic nerve traffic) is already evident in the initial stages of the disease (NYHA classes I-II) and more manifest in severe heart failure (NYHA classes III-IV). Although representing in mild heart failure a compensatory mechanism aimed at preserving cardiac output, the sympathetic and neurohumoral activation, which can be likely ascribed to arterial baroreceptor dysfunction, may represent, in the clinical course of the disease, a maladaptative phenomenon. Thus pharmacological treatment of heart failure should be aimed not only at improving systemic haemodynamics but also at reversing neurohumoral activation and baroreflex impairment. Recent experimental clinical evidence suggests that these therapeutical goals can be satisfactorily achieved by digitalis glycosides and ACE-inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=0028523403&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028523403&partnerID=8YFLogxK

M3 - Articolo

VL - 9 Suppl

JO - Annali Italiani di Medicina Interna

JF - Annali Italiani di Medicina Interna

SN - 0393-9340

ER -